Human Phospho-ErbB3/Her3 DuoSet IC ELISA, 2 Plate

The human breast cancer cell line, MDA-MB-453, was treated with 100 ng/mL recombinant HRG-beta 1 (Catalog # 396-HB) for five minutes to induce tyrosine phosphorylation of ErbB3. Serial dilutions of lysates were analyzed by R&D Systems’ Phospho-ErbB3 DuoSet IC ELISA (Catalog # DYC1769) and by IP-Western blot (inset). For IP-Westerns, IPs were done using anti-ErbB3 monoclonal antibody and anti-mouse IgG agarose. Immunoblots were incubated with biotinylated anti-phosphotyrosine monoclonal antibody (Cat # BAM1676) to detect phospho-ErbB3. Bands were visualized with Streptavidin-HRP (Cat # DY998) followed by ECL detection. ErbB3 was observed at its predicted size (inset; 185 kDa, arrow) in Western blot analysis.

MDA-MB-453 cells were untreated or treated with 100 ng/mL of recombinant HRG-beta 1 (Catalog # 396-HB) for five minutes. Cell lysates (100 μg) were analyzed by R&D Systems’ Phospho-ErbB3 DuoSet IC ELISA (Catalog # DYC1769) and by IP-Western blot (inset). IP-Western blots for phospho-ErbB3 (p-ErbB3) were done as described in Figure 1. Blots were stripped and total ErbB3 (ErbB3) was detected using biotinylated anti-ErbB3 polyclonal antibody (Catalog # BAF234).

MDA-MB-453 cells were treated with 100 ng/mL of recombinant HRG-beta 1 (Catalog # 396-HB) for five minutes. The indicated amounts of ErbB3 (Catalog # 348-ER), ErbB2 (Catalog # 1129-ER) or EGF R (Catalog # 1095-ER) recombinant extracellular domains were added to 5 μg lysate and analyzed using R&D Systems’ Human Phospho-ErbB3 DuoSet IC ELISA (Catalog # DYC1769). Competition was observed only with recombinant ErbB3.

• Reactivity: Hu
• Applications: ELISA
• Conjugate: Biotin

Human Phospho-ErbB3/Her3 DuoSet IC ELISA, 2 Plate Summary

• Source: N/A
• Assay Type: Solid Phase Sandwich ELISA
• Inter-Assay: See PDF Datasheet for details
• Intra-Assay: See PDF Datasheet for details
• Spike Recovery: See PDF Datasheet for details
• Sample Volume: See PDF Datasheet for details
• Gene: ERBB3

Applications/Dilutions

• Dilutions:
  • ELISA
• Application Notes: No significant interference observed with available related molecules.

Packaging, Storage & Formulations

• Storage: Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Human Phospho-ErbB3/Her3 DuoSet IC ELISA, 2 Plate

• c-erbB3
• EC 2.7.10
• EC 2.7.10.1
• ErbB3
• ErbB-3
• erbB3-S
• HER3
• HER3c-erbB-3
• LCCS2
• lethal congenital contracture syndrome 2
• MDA-BF-1
• MGC88033
• p180-ErbB3
• p45-sErbB3
• p85-sErbB3
• Proto-oncogene-like protein c-ErbB-3
• receptor tyrosine-protein kinase erbB-3
• Tyrosine kinase-type cell surface receptor HER3
• v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian)

Background

ErbB3, also called Her3 (human epidermal growth factor receptor 3) in humans, is a type I transmembrane glycoprotein that is a member of the ErbB family of tyrosine kinase receptors. ErbB3 binds neuregulins NRG1 and NRG2, but lacks a working kinase domain; heterodimerization with another ErbB receptor is required for signaling. ErbB3 is important in development of Schwann cells, neural crest cells, heart valves and the sympathetic nervous system. When expressed with ErbB2 in breast, skin, ovary and gastrointestinal tumors, ErbB3 is a potent mitogen.

Publications for ErbB3/Her3 (DYC1769-2)(4)

Publications using DYC1769-2

• CD Leitao, SS Rinne, M Altai, O Vorontsova, F Dunås, P Jonasson, V Tolmachev, J Löfblom, S Ståhl, A Orlova Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model Pharmaceutics, 2020-06-13;12(6):. 2020-06-13 [PMID: 32545760] (Human)
• Ekerljung L, Lennartsson J, Gedda L The HER2-binding affibody molecule (Z(HER2ratio342))(2) increases radiosensitivity in SKBR-3 cells. PLoS ONE, 2012-11-14;7(11):e49579. 2012-11-14 [PMID: 23166716] (Human)
• Gostring L, Malm M, Hoiden-Guthenberg I, Frejd FY, Stahl S, Lofblom J, Gedda L Cellular Effects of HER3-Specific Affibody Molecules. PLoS ONE, 2012-06-29;7(6):e40023. 2012-06-29 [PMID: 22768204] (Human)
• Hickinson DM, Klinowska T, Speake G AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer. Clin. Cancer Res., 2010-02-09;16(4):1159-69. 2010-02-09 [PMID: 20145185] (Human)

FAQs for ErbB3/Her3 (DYC1769-2). (Showing 1 - 1 of 1 FAQs).

1. What is the difference between the Quantikine and Duoset ELISA kits?
   • Our Quantikine kits are fully optimized and validated for the sample types listed on the product specific webpage and datasheet, as this can vary between kits. Each kit is supplied ready to use with one pre-coated 96-well plate, a detection antibody directly conjugated to HRP, and all other necessary reagents. These kits are ideal for researchers who want the convenience of a ready to use and optimized ELISA product. Some of these kits are also available prepackaged in larger 6 and 50 plate sizes.Our DuoSet Kits, in contrast, are ELISA development kits containing the capture and detection antibody, the mass-value calibrated standard, and streptavidin-HRP to prepare approximately 5 or 15 plates. Ancillary reagents will need to be used/purchased, and for most kits, we will recommend one of our Ancillary Reagent Kits, which contain the reagents we use ourselves in-house. DuoSet kits are validated only for cell culture supernatant samples and therefore require further development and validation for accurate measurement in more complex samples such as serum and plasma. Our DuoSet Kits offer an economical, flexible alternative for the experienced ELISA user.

Bioinformatics

• Gene Symbol: ERBB3